Clik here to view.
NIH agency to evaluate Isotechnika’s NICAMs
Isotechnika Pharma (TSX: ISA) has signed a three-year Non-Clinical Evaluation Agreement with the NIH’s National Institute of Allergy and Infectious Diseases (NIAID). Under the accord, NIAID-funded...
View ArticleClik here to view.
Isotechnika’s NICAMs demonstrate anti-viral activity
Isotechnika Pharma (TSX: ISA) announced positive results from the first round of screening of its portfolio of cyclophilin antagonist molecules (NICAMs) through the contract testing laboratories of the...
View ArticleClik here to view.
Isotechnika highlights upcoming milestones in Q3 report
Isotechnika Pharma (TSX:ISA) expects a decision shortly from the International Chamber of Commerce (ICC) Court of Arbitration on its right to terminate a development, distribution and license agreement...
View ArticleClik here to view.
Isotechnika’s NICAMs effective against Hepatitis C virus
Isotechnika Pharma (TSX:ISA) has announced positive anti-hepatitis C virus (HCV) results from the second round of in vitro testing of its cyclophilin antagonist molecules (NICAMs) carried out by the...
View Article
